August 15, 2026 06:31 am (IST)
Follow us:
facebook-white sharing button
twitter-white sharing button
instagram-white sharing button
youtube-white sharing button
Ajit Doval breaks silence on Operation Sindoor in Discovery’s explosive new docuseries | Rahul Gandhi's 'mock hug' taunt sparks row; Centre stresses 'mutual respect' with Italy | Delhi on high alert: Bomb threat to High Court, airport and multiple locations ahead of I-Day | ‘Who are they to interfere?’: CJI Surya Kant slams Bar Council of India over NALSAR students’ enrolment row | 'Shows how low Congress has sunk': BJP slams Rahul Gandhi over Modi foreign policy jibe | From guns to glamour: Former women Maoists walk the ramp in Chhattisgarh | Netaji row: Suvendu Adhikari govt strips BJP MP Anant Maharaj of state honour | Sukhbir Badal attacked by Nihang Sikh with kirpan at Maharashtra gurdwara; assailant detained | ‘If you cannot do it, we will pass an order’: Supreme Court’s final warning to Centre on food labels | ‘Time to move on’: Bombay HC sends strong message in Vijay Mallya-bank dispute
Chinese vaccine
Image: Unsplash

Pakistan says China's Sinopharm vaccine not recommended for people aged above 60

| @indiablooms | Feb 11, 2021, at 04:56 pm

The Chinese Sinopharm vaccine for Covid-19, which started being administered in Pakistan recently, is not recommended for people aged over 60, a top official said.

Speaking to reporters in Islamabad, Special Assistant to the Prime Minister on Health Dr Faisal Sultan was quoted as saying by Dawn News that the government's expert committee while considering the preliminary analysis of Sinopharm data had recommended that the vaccine be licensed for people aged 18-60 "at this stage".

"At this stage, the [committee] did not authorise the vaccine for people older than 60," he added.

When contacted by Dawn News about which vaccine would be used for people over 60 instead of Sinopharm's, Dr Sultan said the AstraZeneca vaccine would be used.

"When our Pakistani experts looked at the data, they were reasonably satisfied with the AstraZeneca data but felt that [based] on the presently available numbers for Sinopharm, the data did not justify its usage for those aged over 60," he said.

"The Chinese have also reiterated this restriction," he added.

Support Our Journalism

We cannot do without you.. your contribution supports unbiased journalism

IBNS is not driven by any ism- not wokeism, not racism, not skewed secularism, not hyper right-wing or left liberal ideals, nor by any hardline religious beliefs or hyper nationalism. We want to serve you good old objective news, as they are. We do not judge or preach. We let people decide for themselves. We only try to present factual and well-sourced news.

Support objective journalism for a small contribution.